Market Place
Sourcing Support
Primmune Secures $22.5 Million Contract to Advance PRTX007 for Lassa Fever
20 Mar 2024 //
BUSINESSWIRE
Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007
10 Nov 2023 //
BUSINESSWIRE
Primmune to Present New Clinical Data from Phase 1 Study Evaluating PRTX007
11 Oct 2023 //
BUSINESSWIRE
Primmune Therapeutics to Present at the 2023 STING & TLR-Targeting Summit
08 May 2023 //
BUSINESSWIRE
Primmune Presents New Clinical Data from Phase 1 Study Evaluating PRTX007
18 Apr 2023 //
BUSINESSWIRE
Primmune to Present New Clinical Data from Phase 1 Study Evaluating PRTX007
14 Mar 2023 //
BUSINESSWIRE
Primmune Tx to Present Interim Data from Phase 1 Study of PRTX007 at 2022 AACR
28 Mar 2022 //
BUSINESSWIRE
Primmune Tx Presents Data Evaluating PRTX007 as an Antiviral at ICAR
21 Mar 2022 //
BUSINESSWIRE
Primmune Tx to Participate in the 32nd Annual Oppenheimer Healthcare Conference
10 Mar 2022 //
BUSINESSWIRE
Primmune Tx to Participate in 12th Annual Biocom GLS Partnering Conference
24 Feb 2022 //
BUSINESSWIRE
Primmune Tx Shows Interim Analysis of Data from Phase 1 Study for PRTX007
14 Feb 2022 //
BUSINESSWIRE
Primmune to Present Data from Phase 1 Study Evaluating PRTX007 at CROI 2022
07 Feb 2022 //
BUSINESSWIRE
Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing
04 Nov 2021 //
PRESS RELEASE
Primmune Provides Update on Phase 1 Healthy Volunteer Study of PRTX007
02 Nov 2021 //
BUSINESSWIRE
Primmune Therapeutics Announces Close of Series A Financing
12 Jan 2021 //
BUSINESSWIRE
Primmune Therapeutics Announces $27.4 Million Series A Financing
27 Oct 2020 //
BUSINESSWIRE
Primmune Therapeutics Announces $27.4 Million Series A Financing
27 Oct 2020 //
BUSINESSWIRE
Primmune Therapeutics Announces the Selection of PRTX007
31 Mar 2020 //
PRNEWSWIRE.COM/NEWS-RELEASES/PRIMMUNE-TH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.